A gene has been identified which is able to detect which patients with a certain type of brain cancer will respond better to treatment, potentially bringing hope to those with the brain injury.
Ohio State University Medical Center researchers found that testing for the gene could differentiate patients with a more or less aggressive form of glioblastoma to help personalise therapy.
Glioblastoma is the most common type of primary brain cancer, and is often fatal.
Co-author Dr Arnab Chakravarti, of the institute, said: "Clearly, all glioblastomas are not the same. Rather, they are a collection of different molecular and genetic entities that behave uniquely and require personalized treatment."
In other news, a study published in the British Journal of Cancer, revealed that the presence of early side effects of chemoradiation such as fatigue and loss of short-term memory were linked to late side effects and overall survival rates of brain cancer patients.
This indicates that the minimisation of side effects from chemoradiation could result in improved survival rates among patients.
News by Serious Law. Expert legal assistance for those affected by brain injury
Posted by Matthew Heap
